Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Equillium Announces Interim Results From EQUALISE Study In With Lupus Nephritis; Says ‘5 of 6 (83%) subjects achieved complete or partial response and 4 of 6 (67%) subjects achieved > 80% reduction in urine protein creatinine ratio (UPCR) by week 28’

Itolizumab demonstrates clinically meaningful response in highly proteinuric subjects: 5 of 6 (83%) subjects achieved complete or partial response and 4 of 6 (67%) subjects achieved > 80% reduction

EQ